Table 1.

Comparison of gene expression changes between early-stage and metastatic colorectal cancers across independent cohorts

This study: stage A vs D (primary)expO: stage A vs D (primary)P
UpregulatedDownregulated
Upregulated134 (57.3%)0 (0%)<0.001
Downregulated0 (0%)100 (42.7%)
This study: stage A vs D (primary)expO: stage A vs D (metastatic deposits)
UpregulatedDownregulated
Upregulated154 (41.3%)10 (2.7%)<0.001
Downregulated5 (1.3%)204 (54.7%)
expO: stage A vs D (primary)expO: stage A vs D (metastatic deposits)
UpregulatedDownregulated
Upregulated414 (49.9%)7 (0.8%)<0.001
Downregulated3 (0.4%)405 (48.9%)

NOTE: Analysis was done for 44 stage A and 61 primary stage D colorectal cancers from this study, 42 stage A and 32 primary stage D colorectal cancers from expO, and 42 stage A colorectal cancers and 30 distant metastases (stage D) from expO. For each cohort, genes (probe sets) differentially expressed between early-stage and metastatic cancers were identified using Significance Analysis of Microarrays and a false discovery rate of 10%. For genes repeatedly identified between cohorts, consistency of upregulation or downregulation in metastatic cancers was assessed using Pearson's χ2 test.